ONESTOCK/SUMMIT-PARTNERS
21.5.2024 08:01:34 CEST | Business Wire | Press release
OneStock SAS, a leading provider of Order Management Systems (OMS), today announced a $72 million investment from global growth equity investor Summit Partners.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240520891262/en/
Founders Benoit Baccot and Romulus Grigoras, OneStock (Photo: Business Wire)
OneStock was founded in 2015 by CEO, Romulus Grigoras, and CTO, Benoit Baccot, to help retailers and brands navigate the increasing complexity of the omnichannel landscape and enhance overall customer experience. The company’s cloud-native solution provides a centralised platform designed to manage end-to-end order fulfillment and visibility and empower retailers to offer a seamless ‘buy anywhere, deliver anywhere, return anywhere’ experience to customers.
"Since the beginning, OneStock has been dedicated to creating smarter and more sustainable shopping experiences, and our partnership with Summit marks a thrilling new chapter in our journey, reaffirming our long-term commitment to innovation and growth in the retail technology space,” commented Mr. Grigoras. “With Summit's support and the benefit of their deep experience in the retail technology sector, we're poised to accelerate our growth even further. Our clear ambition is to emerge as the number one global leader in the OMS category.”
Offering a highly compelling customer ROI and a feature-rich, user-centric solution, OneStock has experienced robust, profitable growth in recent years, achieving a 2.5-fold increase in recurring revenue since 2021. The company has seen widespread adoption amongst major enterprise customers across diverse verticals, ranging from luxury goods to car parts, pet food to furniture, and from traditional B2C retailers to franchiser networks and B2B commerce. Today, more than 100 international retailers and brands across 25 countries leverage OneStock, with the platform facilitating over €2.5 billion in orders annually. OneStock customers include Yves Rocher, WHSmith, Intersport, ManoMano, and S.Oliver.
“With the proliferation of online and offline sales channels and consumers’ ever-increasing expectations for instant product availability and fulfillment, we believe a modern OMS has become a critical part of the retail supply chain. In our view, OneStock has developed the most intuitive, scalable and differentiated cloud-native OMS solutions, purpose-built to help brands and retailers to plan better, grow faster, sell more and waste less,” comments Steffan Peyer, a Managing Director at Summit Partners who will join the OneStock Board of Directors.
This new funding will be used to fuel OneStock’s continued international expansion, particularly into the U.S. market, and to help accelerate the company’s vision for a retail landscape where order management is seamless and easy. OneStock is a proud Adobe Gold Partner, one of the select few MACH-certified OMS providers in the MACH Alliance, and the first OMS with an official integration with Shopify. The company aims to become the easiest-to-integrate OMS in the market by expanding its partner relationships, by extending the comprehensive range of integrations offered in the OneStock Extensions Portal and by soon opening its platform to external agencies and customers seeking to develop additional extensions for particular use cases and verticals. In addition, the company plans to accelerate product development in a number of areas, including B2B, AI and circular economy initiatives.
“OneStock is known in the retail market for having an impressive track record of innovation, including what we believe are pioneering features such as gamification as part of its Ship from Store product, its advanced Business Intelligence Suite, and one of the most sophisticated Delivery Promise solutions in the industry,” said Nik Ohri, a Vice President at Summit Partners who will also join the OneStock Board of Directors.
“We are thrilled to partner with this highly experienced team, and we look forward to working with Romulus and Benoit to help accelerate their vision and expand the reach of OneStock’s impact globally.”
Mr. Grigoras added: “I want to extend my heartfelt thanks to the entire OneStock team and all of our partners and customers, whose hard work and collaboration have been instrumental in helping OneStock achieve this fantastic milestone. We remain committed to supporting the success of our customers as we continue to shape the future of retail!”
About OneStock
OneStock is Europe’s market-leading distributed order management system provider. We help retailers unlock their full omnichannel potential and power some of the world’s most convenient shopping experiences. Our cloud-native SaaS solution improves operational efficiency, increases online revenue and enhances customer experience.
A single view of inventory across all stock locations enables our clients to maximise sales opportunities, enhance fulfilment options, optimise order orchestration, create new omnichannel capabilities, seamlessly manage returns and analyse business performance. OneStock is a proud member of the MACH Alliance and provides best-of-breed solutions for many brands, including: Pets at Home, Jigsaw, Hackett, The Perfume Shop, Dune and Moss. For more information, visit onestock-retail.com.
About Summit Partners
Founded in 1984, Summit Partners is a global alternative investment firm with capital dedicated to growth equity, fixed income, and public equity opportunities. Summit invests across growth sectors of the economy and has invested in more than 550 companies in technology, healthcare, and other growth industries. Notable investments in the retail technology and marketing technology sectors include RELEX, Akeneo, Klaviyo, Optimove, Later and Mi9 Retail. Summit maintains offices in North America and Europe and invests in companies around the world. For more information, please see www.summitpartners.com or Follow on LinkedIn.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240520891262/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom